CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-695.4%−527.2 pts over 5 years
Net margin
-891.6%−663.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +376.6% | -2.4% | +9.5% | +11.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 20.2% | -248.5% | 197.5% | |
| Return on assets | 11.5% | -30.9% | -55.5% | |
| Current ratio | 4.77 | 15.20 | 4.53 | |
| Debt to equity | 0.32 | 0.41 | -0.44 | |
| Net debt to EBITDA | -1.90× | 0.40× | -0.27× | |
| Interest coverage | 6.9× | -5.9× | -13.4× | |
| Capex to revenue | 1.5% | 19.8% | 28.2% | |
| Diluted shares | 43M | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cytokinetics generated $1.76B from operations and spent $90.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.76B
Used
$90.34M
Capital expenditure$90.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-891.6%
×Asset turnover0.06×
×Equity multiplier-3.55×
=Return on equity, FY2025197.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -891.6% | 0.06× | -3.55× | 197.5% |
| FY2024 | -3191.1% | 0.02× | -4.27× | 226.0% |
| FY2023 | -6988.6% | 0.01× | -3.72× | 213.0% |
| FY2022 | -411.2% | 0.10× | 13.65× | -572.1% |
| FY2021 | -305.7% | 0.10× | 3.85× | -120.5% |
| FY2020 | -228.0% | 0.14× | 8.04× | -248.5% |
| FY2019 | -452.9% | 0.11× | 33.41× | -1622.9% |
| FY2018 | -337.4% | 0.12× | 3.73× | -156.6% |
| FY2017 | -955.9% | 0.06× | 2.28× | -125.2% |
| FY2016 | 15.5% | 0.75× | 1.75× | 20.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$784.96M
- Cash generatingOperating cash flow above zero-$510.01M
- Return on assets improvedROA up on the prior year-71.5% → -56.0%
- Earnings backed by cashOperating cash flow above net income-$510.01M vs -$784.96M
- Less leverageLong-term debt to assets fell6.7% → 17.3%
- Better liquidityCurrent ratio rose6.17 → 4.53
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.06